Is PDS Biotechnology Stock a Good Investment?
PDS Biotechnology Investment Advice | PDSB |
- Examine PDS Biotechnology's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research PDS Biotechnology's leadership team and their track record. Good management can help PDS Biotechnology navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact PDS Biotechnology's business and its evolving consumer preferences.
- Compare PDS Biotechnology's performance and market position to its competitors. Analyze how PDS Biotechnology is positioned in terms of product offerings, innovation, and market share.
- Check if PDS Biotechnology pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about PDS Biotechnology's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in PDS Biotechnology Corp stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if PDS Biotechnology Corp is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Very risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine PDS Biotechnology Stock
Researching PDS Biotechnology's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The book value of the company was at this time reported as 0.6. The company recorded a loss per share of 1.17. PDS Biotechnology Corp last dividend was issued on the 18th of March 2019. The entity had 1:20 split on the 18th of March 2019.
To determine if PDS Biotechnology is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding PDS Biotechnology's research are outlined below:
| PDS Biotechnology generated a negative expected return over the last 90 days | |
| PDS Biotechnology has high historical volatility and very poor performance | |
| PDS Biotechnology may become a speculative penny stock | |
| PDS Biotechnology has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (42.94 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| PDS Biotechnology Corp currently holds about 52.98 M in cash with (33.64 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.86, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| PDS Biotechnology has a frail financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: PDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer Conference |
PDS Biotechnology uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in PDS Biotechnology Corp. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to PDS Biotechnology's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact PDS Biotechnology's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises PDS Biotechnology's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-11-10 | 2021-09-30 | -0.2 | -0.24 | -0.04 | 20 | ||
2020-08-13 | 2020-06-30 | -0.23 | -0.19 | 0.04 | 17 | ||
2021-05-13 | 2021-03-31 | -0.19 | -0.14 | 0.05 | 26 | ||
2024-05-15 | 2024-03-31 | -0.37 | -0.3 | 0.07 | 18 | ||
2022-08-08 | 2022-06-30 | -0.28 | -0.2 | 0.08 | 28 | ||
2024-03-27 | 2023-12-31 | -0.44 | -0.35 | 0.09 | 20 | ||
2020-11-11 | 2020-09-30 | -0.14 | -0.23 | -0.09 | 64 | ||
2023-11-14 | 2023-09-30 | -0.45 | -0.35 | 0.1 | 22 |
Know PDS Biotechnology's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as PDS Biotechnology is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading PDS Biotechnology Corp backward and forwards among themselves. PDS Biotechnology's institutional investor refers to the entity that pools money to purchase PDS Biotechnology's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Integrys Wealth Advisors Llc | 2024-12-31 | 73.5 K | Two Sigma Investments Llc | 2024-12-31 | 65.7 K | Virtu Financial Llc | 2024-12-31 | 54.7 K | Ubs Group Ag | 2024-12-31 | 50.1 K | Vontobel Holding Ltd. | 2024-12-31 | 40 K | Marshall Wace Asset Management Ltd | 2024-12-31 | 39 K | Jane Street Group Llc | 2024-12-31 | 35.6 K | Bank Of New York Mellon Corp | 2024-12-31 | 29.3 K | Bank Of America Corp | 2024-12-31 | 26.9 K | Vanguard Group Inc | 2024-12-31 | 1.5 M | Blackrock Inc | 2024-12-31 | 523.1 K |
PDS Biotechnology's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 61.09 M.Market Cap |
|
PDS Biotechnology's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.65) | (0.68) | |
| Return On Capital Employed | (1.08) | (1.14) | |
| Return On Assets | (0.65) | (0.68) | |
| Return On Equity | (1.89) | (1.80) |
Determining PDS Biotechnology's profitability involves analyzing its financial statements and using various financial metrics to determine if PDS Biotechnology is a good buy. For example, gross profit margin measures PDS Biotechnology's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of PDS Biotechnology's profitability and make more informed investment decisions.
Please note, the presentation of PDS Biotechnology's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, PDS Biotechnology's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of PDS Biotechnology's management manipulating its earnings.
Evaluate PDS Biotechnology's management efficiency
PDS Biotechnology Corp has return on total asset (ROA) of (0.4488) % which means that it has lost $0.4488 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.7449) %, meaning that it created substantial loss on money invested by shareholders. PDS Biotechnology's management efficiency ratios could be used to measure how well PDS Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities. As of March 26, 2025, Return On Tangible Assets is expected to decline to -0.68. In addition to that, Return On Capital Employed is expected to decline to -1.14. The current year's Net Tangible Assets is expected to grow to about 53.1 M, whereas Total Assets are forecasted to decline to about 64.9 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.97 | 0.92 | |
| Tangible Book Value Per Share | 0.97 | 0.92 | |
| Enterprise Value Over EBITDA | (2.72) | (2.86) | |
| Price Book Value Ratio | 5.30 | 5.56 | |
| Enterprise Value Multiple | (2.72) | (2.86) | |
| Price Fair Value | 5.30 | 5.56 | |
| Enterprise Value | 294.4 M | 309.2 M |
Leadership at PDS Biotechnology emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Beta 1.671 |
Basic technical analysis of PDS Stock
As of the 26th of March, PDS Biotechnology holds the Risk Adjusted Performance of (0.05), coefficient of variation of (1,482), and Market Risk Adjusted Performance of (0.43). Concerning fundamental indicators, the technical analysis model allows you to check practical technical drivers of PDS Biotechnology, as well as the relationship between them.PDS Biotechnology's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific PDS Biotechnology insiders, such as employees or executives, is commonly permitted as long as it does not rely on PDS Biotechnology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases PDS Biotechnology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
PDS Biotechnology's Outstanding Corporate Bonds
PDS Biotechnology issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. PDS Biotechnology Corp uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most PDS bonds can be classified according to their maturity, which is the date when PDS Biotechnology Corp has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US70462GAC24 Corp BondUS70462GAC24 | View | |
| US70462GAB41 Corp BondUS70462GAB41 | View |
Understand PDS Biotechnology's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing PDS Biotechnology's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.05) | |||
| Market Risk Adjusted Performance | (0.43) | |||
| Mean Deviation | 4.48 | |||
| Coefficient Of Variation | (1,482) | |||
| Standard Deviation | 6.16 | |||
| Variance | 37.99 | |||
| Information Ratio | (0.07) | |||
| Jensen Alpha | (0.43) | |||
| Total Risk Alpha | (0.45) | |||
| Treynor Ratio | (0.44) | |||
| Maximum Drawdown | 33.91 | |||
| Value At Risk | (9.22) | |||
| Potential Upside | 9.21 | |||
| Skewness | 1.06 | |||
| Kurtosis | 2.49 |
| Risk Adjusted Performance | (0.05) | |||
| Market Risk Adjusted Performance | (0.43) | |||
| Mean Deviation | 4.48 | |||
| Coefficient Of Variation | (1,482) | |||
| Standard Deviation | 6.16 | |||
| Variance | 37.99 | |||
| Information Ratio | (0.07) | |||
| Jensen Alpha | (0.43) | |||
| Total Risk Alpha | (0.45) | |||
| Treynor Ratio | (0.44) | |||
| Maximum Drawdown | 33.91 | |||
| Value At Risk | (9.22) | |||
| Potential Upside | 9.21 | |||
| Skewness | 1.06 | |||
| Kurtosis | 2.49 |
Consider PDS Biotechnology's intraday indicators
PDS Biotechnology intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of PDS Biotechnology stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
PDS Biotechnology time-series forecasting models is one of many PDS Biotechnology's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary PDS Biotechnology's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
PDS Stock media impact
Far too much social signal, news, headlines, and media speculation about PDS Biotechnology that are available to investors today. That information is available publicly through PDS media outlets and privately through word of mouth or via PDS internal channels. However, regardless of the origin, that massive amount of PDS data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of PDS Biotechnology news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of PDS Biotechnology relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to PDS Biotechnology's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive PDS Biotechnology alpha.
PDS Biotechnology Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards PDS Biotechnology can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
PDS Biotechnology Corporate Management
| Joe Dervan | VP Development | Profile | |
| Lars MBA | Chief Officer | Profile | |
| Deanne Randolph | Head Relations | Profile | |
| Gregory Conn | Chief Scientific Officer | Profile | |
| Spencer JD | Senior Counsel | Profile | |
| Nathalie Riebel | VP Operations | Profile | |
| Janetta Trochimiuk | Controller | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PDS Biotechnology Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PDS Biotechnology. If investors know PDS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PDS Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of PDS Biotechnology Corp is measured differently than its book value, which is the value of PDS that is recorded on the company's balance sheet. Investors also form their own opinion of PDS Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is PDS Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PDS Biotechnology's market value can be influenced by many factors that don't directly affect PDS Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between PDS Biotechnology's value and its price, as these two are different measures arrived at by various means. Investors typically determine if PDS Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PDS Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.